Assessment tools for patient-reported outcomes in multiple myeloma
- PMID: 37389673
- PMCID: PMC10313577
- DOI: 10.1007/s00520-023-07902-4
Assessment tools for patient-reported outcomes in multiple myeloma
Abstract
Background: Patients with multiple myeloma experience severe symptom burden. Patient participation in self-reporting is essential as medical staff's assessment of patient symptom severity is often lower than patient self-reporting. This article reviews patient-reported outcome (PRO) assessment tools and their application in the field of multiple myeloma.
Results: The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) is the universal patient-reported outcome assessment tool most frequently used to evaluate the life quality in people with multiple myeloma. Among the specific patient-reported outcome assessment tools, the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Multiple Myeloma Module (EORTC QLQ-MY20), the Functional Assessment of Cancer Therapy-Multiple Myeloma (FACT-MM), and the M.D. Anderson Symptom Inventory-Multiple Myeloma Module (MDASI-MM) are the most widely used, with some scholars using the EORTC QLQ-MY20 as a calibration correlate for scale development. Most current assessment instruments were developed using classical measurement theory methods; future researchers could combine classic theory tests and item response theory to create scientific assessment instruments. In addition, researchers select the appropriate assessment tool based on the purpose of the study. They can translate high-quality assessment tools into different languages and consider applying them more often to assessing multiple myeloma patients. Finally, most existing PROs focus on measuring life quality and symptoms in people with multiple myeloma, with less research on outcomes such as adherence and satisfaction, thus failing to comprehensively evaluate the patient treatment and disease management.
Conclusions: Research has shown that the field of PROs in multiple myeloma is in an exploratory phase. There is still a need to enrich the content of PROs and develop more high-quality PRO scales for multiple myeloma based on the strengths and weaknesses of existing tools. With the successful advancement of information technology, PROs for people with multiple myeloma could be integrated with electronic information systems, allowing patients to report their health status in real time and doctors to track their condition and adjust their treatment, thereby improving patient outcomes.
Keywords: Assessment tools; Multiple myeloma; Nursing care; Patient-reported outcomes.
© 2023. The Author(s).
Conflict of interest statement
The authors declare no competing interests.
Similar articles
-
Validation of the M. D. Anderson Symptom Inventory multiple myeloma module.J Hematol Oncol. 2013 Feb 5;6:13. doi: 10.1186/1756-8722-6-13. J Hematol Oncol. 2013. PMID: 23384030 Free PMC article.
-
Reliability and Validity of an Iranian Version of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire for Patients with Multiple Myeloma: the EORTC QLQ-MY20.Asian Pac J Cancer Prev. 2016;17(1):255-9. doi: 10.7314/apjcp.2016.17.1.255. Asian Pac J Cancer Prev. 2016. PMID: 26838220
-
Assessment of the psychometric properties of the Spanish version of EORTC QLQ-MY20 and evaluation of health-related quality of Life outcomes in patients with relapsed and/or refractory multiple myeloma in the real-world setting in Spain: results from the CharisMMa study.Leuk Lymphoma. 2023 Nov-Dec;64(11):1847-1856. doi: 10.1080/10428194.2023.2240922. Epub 2023 Aug 4. Leuk Lymphoma. 2023. PMID: 37539698
-
Use of the European Organisation for Research and Treatment of Cancer multiple myeloma module (EORTC QLQ-MY20): a review of the literature 25 years after development.Blood Cancer J. 2023 May 16;13(1):79. doi: 10.1038/s41408-023-00815-9. Blood Cancer J. 2023. PMID: 37193682 Free PMC article. Review.
-
The Reporting, Use, and Validity of Patient-Reported Outcomes in Multiple Myeloma in Clinical Trials: A Systematic Literature Review.Cancers (Basel). 2022 Dec 6;14(23):6007. doi: 10.3390/cancers14236007. Cancers (Basel). 2022. PMID: 36497488 Free PMC article. Review.
Cited by
-
How First-Line Therapy is Changing in non-Transplant Eligible Multiple Myeloma Patients.Mediterr J Hematol Infect Dis. 2025 Mar 1;17(1):e2025025. doi: 10.4084/MJHID.2025.025. eCollection 2025. Mediterr J Hematol Infect Dis. 2025. PMID: 40084107 Free PMC article. Review.
-
Pain Management in Multiple Myeloma Patients: A Literature Review.Cureus. 2024 Mar 11;16(3):e55975. doi: 10.7759/cureus.55975. eCollection 2024 Mar. Cureus. 2024. PMID: 38601412 Free PMC article. Review.
-
Predictive and Prognostic Significance of Patient-Reported Outcomes for Survival and Adverse Events in Daratumumab-Treated Multiple Myeloma.Eur J Haematol. 2025 Jun;114(6):1020-1031. doi: 10.1111/ejh.14410. Epub 2025 Mar 14. Eur J Haematol. 2025. PMID: 40084510 Free PMC article.
-
Psychometric Evaluation of the Chinese Version of the Quality-of-Life Questionnaire for Patients with Multiple Myeloma.Palliat Med Rep. 2025 Mar 3;6(1):98-104. doi: 10.1089/pmr.2024.0086. eCollection 2025. Palliat Med Rep. 2025. PMID: 40151515 Free PMC article.
References
-
- Yan Z, Liya Q, Rui C, et al. Identification and emergency care of sudden loss of consciousness in patients with multiple myeloma complicated with myocardial amyloidosis. Chin J Emerg Crit Care Nurs. 2022;3(4):335–337. doi: 10.3761/j.issn.2096-7446.2022.04.008. - DOI
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous